Document 2874
 DOCN  M94A2874
 TI    Nimodipine+ZDV vs ZDV in patients with ADC.
 DT    9412
 AU    Galgani S; Narciso P; Balestra P; Pigorini F; Pau F; Sette P; Tozzi V;
       Alba L; Grisetti S; Visco G; USLRM10, Rome, Italy.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):205 (abstract no. PB0248). Unique
       Identifier : AIDSLINE ICA10/94369701
 AB    OBJECTIVE. To evaluate the activity of ZDV+Nimodipine (NMP) (an oral
       calcium-channel blocking agent that may reduce HIV-induced neurotoxicity
       in vitro) association in the treatment of HIV-induced cognitive
       dysfunctions. METHODS. Design: open, case control study. Eligibility
       criteria:CD4 cells < 500/mmc, ADC staging 0, 0.5, 1.2 (Price criteria).
       Treatment regimens: NMP 90 mg/qd+ZDV 250 mg/bid vs ZDV 250 mg/bid.
       Follow-up: laboratory controls every month, neurological examination
       every 3 months, neuropsychological evaluations exploring attention,
       memory, reasoning every 6 months, 99-mtc-HM-PAO SPECT exam every 6
       months. Criteria for response: modification of ADC staging,
       neuropsychological testing and SPECT findings. RESULTS. Details of
       patients at enrollment: TABULAR DATA, SEE ABSTRACT VOLUME. Mean
       follow-up was 6 months. After 6 months of treatment pts treated with
       NMP+ZDV showed significantly better neuropsychological performances than
       pts treated with ZDV alone (Wisconsin CSt for categories p = 0.01,
       Wisconsin CSt for perseverative errors p = 0.02, Digit Symbol p = 0.03,
       by ANOVA). No significative difference were seen in SPECT findings
       although pts of the NMP+ZDV group showed a trend toward a development of
       less pronounced up-take deficits. CONCLUSIONS. Pts treated with ZDV+NMP
       show a trend to a better stability over time of neuropsychological
       performance. This phenomenon was mainly observed in test exploring
       frontal lobe functions.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY/PSYCHOLOGY  AIDS
       Dementia Complex/*PREVENTION & CONTROL  Case-Control Studies
       Comparative Study  Drug Evaluation  Drug Therapy, Combination  Human
       Neuropsychological Tests  Nimodipine/ADMINISTRATION &
       DOSAGE/*THERAPEUTIC USE  Treatment Outcome  Zidovudine/ADMINISTRATION &
       DOSAGE/*THERAPEUTIC USE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).